What is Novos?
Founded in 2018 and headquartered in New York City, Novos operates at the intersection of data science and wellness. The company distinguishes itself by providing consumers with well-tested nutraceuticals, meticulously developed based on the latest scientific innovations and discoveries in longevity research. By leveraging a data & research-driven methodology, Novos aims to offer scientifically validated products that support healthy aging and enhance overall well-being.
How much funding has Novos raised?
Novos has raised a total of $3.1M across 1 funding round:
Unspecified
$3.1M
Unspecified (2021): $3.2M with participation from Resolute.Vc, Longevitytech.Fund, Awesome People Ventures, and Arkitekt Ventures
Key Investors in Novos
Resolute.Vc
Resolute Ventures is an early-stage investor focused on supporting founders at the pre-seed and seed stages, emphasizing community and mentorship to help entrepreneurs build successful ventures.
Longevitytech.Fund
Longevitytech.fund specializes in global investments in technologies aimed at extending healthy lifespans, supporting innovations that improve health outcomes through advanced technological solutions.
Awesome People Ventures
Awesome People Ventures invests in exceptional founders at the pre-seed and seed stages, with a particular focus on innovative projects within the web3 space, aiming to empower creators of remarkable products and services.
What's next for Novos?
The substantial enterprise-level funding and strategic investment signal a pivotal growth phase for Novos. This capital infusion is expected to accelerate product development, expand research initiatives, and bolster market penetration. With a focus on innovation and scientific validation, Novos is well-positioned to capitalize on the burgeoning longevity market. Future strategic moves will likely involve scaling operations, forging key partnerships, and further solidifying its reputation as a leader in data-driven nutraceuticals.
See full Novos company page
